UBS analyst Dan Leonard raised the firm’s price target on Illumina (ILMN) to $110 from $98 and keeps a Neutral rating on the shares. The Q2 beat and raise featured persisting academic pressures, but “resilient” consumables, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $106 from $105 at Baird
- Illumina price target raised to $105 from $99 at Canaccord
- Illumina price target raised to $90 from $85 at Barclays
- Illumina’s Strategic Concerns and Uncertain Outlook: Sell Rating Reiterated with Lowered Price Objective
- Illumina’s Q2 2025 Earnings and Strategic Moves